SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Gritstone bio, Inc. (GRTS) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+14403.1%).
- Analyst consensus target $4.67 (+14403.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GRTS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.79
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.20
Book Value / Share$0.00
Revenue / Share$0.01
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$4.67 (+14403.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.93 |
$0.00 |
$-18.75M |
- |
| 2017 |
$-2.06 |
$0.00 |
$-41.38M |
- |
| 2018 |
$-7.26 |
$1.19M |
$-64.78M |
-5457% |
| 2019 |
$-2.71 |
$4.37M |
$-90.93M |
-2083.1% |
| 2020 |
$-2.77 |
$4.04M |
$-104.61M |
-2591.3% |
| 2021 |
$-0.95 |
$46.72M |
$-74.96M |
-160.4% |
| 2022 |
$-1.24 |
$9.27M |
$-113.13M |
-1220.5% |
| 2023 |
$-1.20 |
$1.33M |
$-138.49M |
-10405% |
